Show Summary Details
Page of

Treatments that may affect the underlying course of MS 

Treatments that may affect the underlying course of MS
Treatments that may affect the underlying course of MS

John Zajicek

, Jennifer Freeman

, and Bernadette Porter

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 08 August 2020

Introduction 124

Beta-interferon 126

Glatiramer acetate 134

Mitoxantrone 136

Cladribine 138

Azathioprine 140

Pooled immunoglobulins 142

Methotrexate 144

Cyclosporin 146

Cyclophosphamide 146

Alemtuzumab (Campath® 1H) 148

Natalizumab (Antegren®, Tysabri®) 150

Treatments for progressive disease 152

In considering the options, the reader is referred to ...

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.